Radiotracer and Microscopic Assessment of Vascular Function in Cancer Therapy

G. M. Tozer, Vincent Joseph Cunningham

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)


Vascular disrupting cancer therapy is aimed at causing a rapid shut-down of the established tumour blood supply, sufficient to induce secondary tumour cell death. It is conceptually distinct from anti-angiogenic therapy, which aims to prevent neo-vascularization of solid tumours. Several low molecular weight drugs have recently entered clinical trial as vascular disrupting agents or VDAs. The lead compound is the tubulin-binding, microtubule depolymerising agent, disodium combretastatin A4 3-O-phosphate (CA-4-P). Tissue blood flow rate (F) is a critical parameter for assessing functional efficiency of a blood vessel network following VDA treatment. CA-4-P causes almost complete cessation of blood flow in many tumour models within I hour of a moderate single dose of CA-4-P. Significant tumour blood flow shut-down has also been observed in clinical trials, without vascular damage in normal tissues. However, reasons for tumour selectivity of VDAs such as CA-4-P remain unclear. Here, we describe methods for evaluating vascular effects of VDAs in pre-clinical models of cancer and the current status of VDA treatments.

Original languageEnglish
Title of host publication11th Mediterranean Conference on Medical and Biomedical Engineering and Computing 2007
EditorsTomaz Jarm, Peter Kramar, Anze Zupanic
Place of PublicationBerlin, Germany
Number of pages4
ISBN (Electronic)9783540730446
ISBN (Print)9783540730439
Publication statusPublished - 2007
EventMEDICON - Ljubljana, Slovenia
Duration: 26 Jun 200730 Jun 2007

Publication series

NameIFMBE Proceedings
ISSN (Print)1680-0737
ISSN (Electronic)1433-9277




  • cancer therapy
  • vascular disruption
  • blood flow rate
  • intravital microscopy
  • combretastatin
  • combretastatin A-4
  • blood-flow
  • tumor
  • agent
  • phosphate


Dive into the research topics of 'Radiotracer and Microscopic Assessment of Vascular Function in Cancer Therapy'. Together they form a unique fingerprint.

Cite this